MASCC Febrile Neutropenia in Patients Treated with Chemotherapy/Immune Checkpoint Inhibition

from Clinical Guideline InSights · host Guideline Central

The 2026 Febrile Neutropenia in Patients Treated with Chemotherapy/Immune Checkpoint Inhibition consensus statement, highlighting key position points across MASCC scoring, treatment, and more. Febrile Neutropenia in Patients Treated with Chemotherapy/Immune Checkpoint InhibitionMultinational Association of Supportive Care in CancerJuly 29, 2026Guideline Summary: https://www.guidelinecentral.com/guideline/5239329/ Full-Text: https://link.springer.com/article/10.1007/s00520-026-11045-7

Episode metadata supplied by the publisher feed · Published Aug 10, 2026

Embed this episode

Attribution link and audio player

Ready to play

MASCC Febrile Neutropenia in Patients Treated with Chemotherapy/Immune Checkpoint Inhibition

0:00 3:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Clinical Guideline InSights?

This episode is 3 minutes long.

When was this Clinical Guideline InSights episode published?

This episode was published on August 10, 2026.

Can I download this Clinical Guideline InSights episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!